Cargando…

An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients

BACKGROUND: The risk of fatal adverse events (FAEs) due to bevacizumab-based chemotherapy has not been well described; we carried out an updated meta-analysis regarding this issue. METHODS: An electronic search of Medline, Embase and The Cochrane Central Register of Controlled Trials was conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Hongxin, Zheng, Yayuan, Zhu, Jianhong, Zhang, Jingjing, Chen, Huapu, Chen, Xinggui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943842/ https://www.ncbi.nlm.nih.gov/pubmed/24599121 http://dx.doi.org/10.1371/journal.pone.0089960

Ejemplares similares

Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma
por: Chen, Jianxin, et al.
Publicado: (2020)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
por: Ngo, Doan T. M., et al.
Publicado: (2020)

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Xuewen, et al.
Publicado: (2020)

Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis
por: Zheng, Yayuan, et al.
Publicado: (2018)

Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
por: Liu, Tingting, et al.
Publicado: (2020)

Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
por: Lai, Xi-Xi, et al.
Publicado: (2016)

Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
por: Wang, Wei, et al.
Publicado: (2014)

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
por: Totzeck, Matthias, et al.
Publicado: (2017)

Meta-Analysis of Long-Term Vitamin D Supplementation on Overall Mortality
por: Zheng, Yayuan, et al.
Publicado: (2013)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Jiang, Yi, et al.
Publicado: (2019)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
por: Hwang, Duck Jin, et al.
Publicado: (2012)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Publicado: (2021)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
por: Song, Zhiqiang, et al.
Publicado: (2023)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Feng, Yao-Ning, et al.
Publicado: (2023)

Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis
por: Zuo, Pei-Yuan, et al.
Publicado: (2014)

Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials
por: Wu, Yu Shen, et al.
Publicado: (2016)

Combined Application of Bevacizumab and Mitomycin C or Bevacizumab and 5-Fluorouracil in Experimental Glaucoma Filtration Surgery
por: Zuo, Lei, et al.
Publicado: (2018)

Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis
por: Xia, Ning, et al.
Publicado: (2015)

Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
por: Li, Xiaofei, et al.
Publicado: (2018)

Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis
por: Wang, Liang, et al.
Publicado: (2017)

A Fatal Adverse Effect of Barbiturate Coma Therapy: Dyskalemia
por: Kwon, Hyun Mook, et al.
Publicado: (2016)

Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials
por: Zhu, Xiaoqiang, et al.
Publicado: (2016)

Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis
por: Zhang, Chun-Jing, et al.
Publicado: (2018)

Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials
por: Sun, Yi, et al.
Publicado: (2018)

Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
por: Kapała, Jan, et al.
Publicado: (2022)

Fatal thyrocardiac event
por: Khutia, Samit Kumar, et al.
Publicado: (2010)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
por: Shin, Sooyoung, et al.
Publicado: (2018)

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Han, Yu Na, et al.
Publicado: (2022)

Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
por: Kumar, Jeevan, et al.
Publicado: (2012)

A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
por: Hayashi, Hidemi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ic45vkq6rfb7bak99erg24o846